Multicenter Glaucoma Study Investigating Standalone Canaloplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-09

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

NCT04769453

Primary Open Angle Glaucoma

TERMINATED NA

Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma

NCT02679482

Glaucoma, Open-Angle Glaucoma, Primary Open Angle Exfoliation Glaucoma +1 more

UNKNOWN

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312

Primary Open-Angle Glaucoma

TERMINATED NA

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973

Primary Open Angle Glaucoma

TERMINATED PHASE4

A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.

NCT00326014

Open-Angle Glaucoma

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iTrack Advance

Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)

Group Type ACTIVE_COMPARATOR

Ab-interno canaloplasty utilizing the iTrack Advance device

Intervention Type DEVICE

360 degree microcatheterization and viscodilation of Schlemm's canal

OMNI Surgical System

Ab-interno canaloplasty utilizing the OMNI Surgical System

Group Type ACTIVE_COMPARATOR

Ab-interno canaloplasty utilizing the OMNI Surgical System

Intervention Type DEVICE

360 degree microcatheterization and viscodilation of Schlemm's canal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ab-interno canaloplasty utilizing the iTrack Advance device

360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention Type DEVICE

Ab-interno canaloplasty utilizing the OMNI Surgical System

360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects, 22 years or older at the time of surgery
* Diagnosed with mild to moderate primary open angle glaucoma
* Candidate for canaloplasty surgery: i.e., catheterization of Schlemm's canal and subsequent viscodilation of Schlemm's canal, without trabeculotomy
* Intolerance to medical therapy OR need/willingness to reduce medications
* At the Screening Visit, IOP of ≤ 30 mmHg while on 1-4 ocular hypotensive medications
* At the Baseline Visit, unmedicated IOP ≥ 21mmHg and ≤ 36 mmHg, and ≥ 3mmHg higher than medicated IOP
* Shaffer grade of ≥ 3 in all four quadrants
* Central corneal thickness ≥ 480µm and ≤ 620 µm
* Able and willing to comply with the study procedures and attend all follow-up visits
* Understands and signs the informed consent

Exclusion Criteria

* Any of the following prior treatments for glaucoma (study eye):

1. Laser trabeculoplasty

i. Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty
2. iStent or iStent Inject within 180 days of the Screening Visit
3. Endocyclophotocoagulation (ECP) or Micropulse laser
4. Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma draining device/valve
5. Prior canaloplasty (ab interno and ab externo)
6. Prior goniotomy, or trabeculotomy (ab externo and ab interno)
7. Hydrus microstent
8. Suprachoroidal stent (e.g., Cypass, iStent Supra, MINIject)
9. Concurrent IOP-lowering procedure other than use of the iTrack Advance canaloplasty device OR the OMNI Surgical System at the time of surgery (e.g., ECP, CPC, etc.)
* Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma
* Cataract surgery within 6 months of the Screening Visit in the study eye
* History of fellow eye with cataract surgery within 30 days of Screening
* Subjects at significant risk by a washout of ocular hypotensive medication, and/or subjects where the unmedicated IOP is expected to exceed the upper limit of 36 mmHg
* Use of systemic medications (either current, within 30 calendar days of Screening exam, or anticipated) that may cause an increase in IOP, (e.g., systemic steroids including inhaled and oral steroids used on a regular basis)
* Ocular and/or systemic diseases that could affect the corneal endothelium (such as corneal endothelial dystrophy, intraocular inflammation and infection, or congenital abnormalities)
* History of penetrating keratoplasty or another corneal transplant
* BCVA of 20/200 or worse in the fellow eye not due to cataract
* Previous treatment with OMNI or iTrack (Note: permitted if fellow eye only was treated)
* BCVA of 20/50 or worse in the study eye not due to posterior capsular opacification

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No